

Jeremy C. Wright • Diane J. Burgess
Editors

Long Acting Injections and Implants

© Wright, Jeremy C.; Burgess, Diane J., Jan 29, 2012, Long Acting Injections and Implants
Springer, New York, ISBN: 9781461405542



Editors

Jeremy C. Wright
DURECT Corporation
Cupertino, CA, USA
jeremy.wright@direct.com

Diane J. Burgess
Department of Pharmaceutical Sciences
School of Pharmacy
University of Connecticut
Storrs, CT, USA
d.burgess@uconn.edu

© Wright, Jeremy C.; Burgess, Diane J., Jan 29, 2012, Long Acting Injections and Implants
Springer, New York, ISBN: 9781461405542

ISSN 2192-6204
ISBN 978-1-4614-0553-5 e-ISBN 978-1-4614-0554-2
DOI 10.1007/978-1-4614-0554-2
Springer New York Dordrecht Heidelberg London

Library of Congress Control Number: 2011937763

© Controlled Release Society, 2012

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Contents

1	An Introduction to Long Acting Injections and Implants	1
	Diane J. Burgess and Jeremy C. Wright	
2	Historical Overview of Long Acting Injections and Implants	11
	Jeremy C. Wright and Allan S. Hoffman	
3	Host Response to Long Acting Injections and Implants	25
	James M. Anderson	
4	Anatomy and Physiology of the Injection Site: Implications for Extended Release Parenteral Systems	57
	Arlene McDowell and Natalie J. Medlicott	
5	Drugs for Long Acting Injections and Implants	73
	Jie Shen and Diane J. Burgess	
6	Diseases and Clinical Applications that Can Benefit from Long Lasting Implants and Injections.....	93
	Roshan James, Udaya S. Toti, Sangamesh G. Kumbar, and Cato T. Laurencin	
7	Oily (Lipophilic) Solutions and Suspensions	113
	Susan W. Larsen, Mette A. Thing, and Claus Larsen	
8	Aqueous Suspensions	137
	Susan M. Machkovech and Todd P. Foster	
9	In Situ Forming Systems (Depots).....	153
	Jeremy C. Wright, Michael Sekar, William van Osdol, Huey Ching Su, and Andrew R. Miksztal	
10	Microsphere Technologies	167
	Yan Wang and Diane J. Burgess	
11	Liposomes as Carriers for Controlled Drug Delivery	195
	Xiaoming Xu and Diane J. Burgess	

12 Micro- and Nanoemulsions (Controlled Release Parenteral Drug Delivery Systems)	221
Jacqueline M. Morais and Diane J. Burgess	
13 Nanosuspensions	239
Sumit Kumar and Diane J. Burgess	
14 PEGylated Pharmaceutical Nanocarriers	263
Vladimir Torchilin	
15 Protein PEGylation	295
Francesco M. Veronese and Gianfranco Pasut	
16 Self-Assembling Lipid Formulations	315
Fredrik Tiberg, Markus Johnsson, Catalin Nistor, and Fredrik Joabsson	
17 Implantable Drug Delivery Systems Based on the Principles of Osmosis	335
John A. Culwell, Jose R. Gadea, Clarisa E. Peer, and Jeremy C. Wright	
18 Microtechnologies for Drug Delivery	359
Kristy M. Ainslie and Tejal A. Desai	
19 Drug-Eluting Stents	383
Jonathon Zhao and Lori Alquier	
20 Delivery of Peptides and Proteins via Long Acting Injections and Implants	409
Cynthia L. Stevenson, Christopher A. Rhodes, and Steven J. Prestrelski	
21 Injectable PLGA Systems for Delivery of Vaccine Antigens	429
Vesna Milacic, Brittany Agius Bailey, Derek O'Hagan, and Steven P. Schwendeman	
22 Methods of Sterilization for Controlled Release Injectable and Implantable Preparations	459
Alpaslan Yaman	
23 In Vitro Drug Release Testing and In Vivo/In Vitro Correlation for Long Acting Implants and Injections	475
Michail Kastellorizios and Diane J. Burgess	
24 Regulatory Issues and Challenges Associated with the Development of Performance Specifications for Modified Release Parenteral Products	505
Marilyn N. Martinez and Mansoor A. Khan	
Index	537

Chapter 4

Anatomy and Physiology of the Injection Site: Implications for Extended Release Parenteral Systems

Arlene McDowell and Natalie J. Medicott

Abstract Understanding how the biological environment contributes to drug release following administration is increasingly becoming a focus for drug delivery research. Achieving therapeutic levels of a bioactive relies on appropriate drug release following parenteral administration that must be complimentary to subsequent drug absorption, distribution, metabolism and elimination. The biological characteristics of the injection site can have an influence on the drug absorption process. In this chapter the intravenous, intramuscular and subcutaneous routes for parenteral administration of extended release products will be discussed.

4.1 Introduction

There are many extended and controlled release injectable systems used to deliver drugs in human and veterinary medicine [1–5]. These systems are prepared from a variety of biocompatible materials and aim to release drug for an extended period following injection or implantation. Drug release is governed by the design of the dosage form, although the biological environment often influences drug release [6–9]. Understanding how the biological environment contributes to drug release following administration is increasingly becoming a focus for drug delivery research.

Extended release parenteral delivery systems range from relatively simple aqueous suspensions that prolong drug release due to slow dissolution at the injection site to more sophisticated in situ gelling implants and polymeric biodegradable microparticulate systems [4, 10, 11]. For example, long acting intramuscular aqueous suspensions of penicillin have been available since the 1950s [12] and oily

A. McDowell • N.J. Medicott (✉)
School of Pharmacy, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand
e-mail: natalie.medlicott@otago.ac.nz

J.C. Wright and D.J. Burgess (eds.), *Long Acting Injections and Implants*,
Advances in Delivery Science and Technology, DOI 10.1007/978-1-4614-0554-2_4,
© Controlled Release Society, 2012

57

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.